University of Cambridge > > Technology Enterprise Group Seminar Series > Biomolecular Design Space and Intellectual Property

Biomolecular Design Space and Intellectual Property

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Dr Thomas Bohné.

Abstract: Biotechnology exhibits several peculiar features. One of them is its chronic ‘immaturity’ leading among others to a somewhat disappointing commercial performance. So far BT has failed to make the expected transition from a predominantly discovery-driven paradigm to a design-driven one. However this may be changing now. We shall discuss these changes using a model which interprets technology as an evolving “design space” and comment on their implications for intellectual property regime, BT’s institutionalization in the research system, and its regulation.

Biography: Rikard Stankiewicz is Professor of Science and Technology Governance at the European University Institute in Florence (Joint Chair in European Studies at the Robert Schuman Centre for Advanced Studies and the Department of Political and Social Sciences). Born in 1941 he studied at Warsaw University and subsequently at Lund University in Sweden where he received a PhD in sociology. In 1988 be became Associate Professor of R&D Management and Policy at the Research Policy Institute, Lund University. Between 1996 and 1998 he served as Professor of Technology Dynamics at the Copenhagen Business School, Denmark.. In 1998 he became Professor of Science and Technology Policy and the director of Research Policy Institute at Lund University. He has conducted research on the organisation and management of research and development in both public and private sectors, university and industry relations, comparative science and technology policy, and technological innovation systems. His most recent research and publications are concerned with the evolutionary models of technological change, science technology-relations, the structure and dynamics of the knowledge base of technology, and the impact of the new biotechnologies on innovation in the healthcare sector.

This talk is part of the Technology Enterprise Group Seminar Series series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity